Status
Conditions
Treatments
About
This study will investigate the use of misoprostol for first-line treatment of incomplete abortion at tertiary hospitals in Myanmar.
Full description
This open-label feasibility study seeks to examine the potential of 400μg sublingual misoprostol for the treatment of incomplete abortion provided at tertiary hospitals.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Confirmed incomplete abortion
No known contraindications to the study drug
Uterine size no larger than 12 weeks at time of presentation for care
No signs of severe infection, defined as at least two of the following:
No hemodynamic disturbances (pulse >110/min and systolic bp <100)
General good health
Agree to comply with study procedures including return for follow up visit
Live or work within one hour from a study site
Willing and able to sign consent forms
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
75 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal